Gilead Sciences revenue
Gilead Sciences's revenue was $29.44bn in fiscal 2025, up 2.4% on the year before. Since fiscal 2009 ($7.01bn) it has grown at a compound 9.4% a year. Over the last twelve months it was $30.99bn.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.0 | 7.9 | 8.4 | 9.7 | 11.2 | 24.9 | 32.6 | 30.4 | 26.1 | 22.1 | 22.4 | 24.7 | 27.3 | 27.3 | 27.1 | 28.8 | 29.4 | 31.0 |
| Growth on the year before | — | +13.4% | +5.5% | +15.7% | +15.5% | +122.2% | +31.1% | −6.9% | −14.1% | −15.2% | +1.5% | +10.0% | +10.6% | −0.1% | −0.6% | +6.0% | +2.4% | — |
| Gross profit | — | — | — | — | — | — | — | 26.1 | 21.7 | 17.3 | 17.8 | 20.1 | 20.7 | 21.6 | 20.6 | 22.5 | 23.2 | 24.8 |
| Gross margin | — | — | — | — | — | — | — | 86.0% | 83.3% | 78.1% | 79.2% | 81.5% | 75.8% | 79.3% | 76.0% | 78.3% | 78.8% | 79.9% |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Products | $28.9B | ▲ 1.1% |
| HIV Product Sales | $20.8B | ▲ 5.8% |
| HIV Products Biktarvy | $14.3B | ▲ 6.8% |
| Oncology Product | $3.2B | ▼ 1.6% |
| Liver Disease | $3.2B | ▲ 6.5% |
| HIV Products Descovy | $2.8B | ▲ 30.5% |
| Cell Therapy Products Total Cell Therapy Product Sales | $1.8B | ▼ 6.8% |
| HIV Products Genvoya | $1.5B | ▼ 15.0% |
| Other Products Yescarta | $1.5B | ▼ 4.8% |
| Trodelvy | $1.4B | ▲ 6.2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $1.3B | ▼ 20.3% |
| HIV Products Odefsey | $1.2B | ▼ 9.4% |
| Liver Disease Products Vemlidy | $1.1B | ▲ 11.6% |
| Veklury | $911M | ▼ 49.4% |
| Liver Disease Products Other Liver Disease | $874M | ▲ 87.2% |
| Other Products Total Other Product Sales | $799M | ▼ 10.1% |
| Royalty Contract and Other | $527M | ▲ 266.0% |
| Other Products Am Bisome | $509M | ▼ 4.5% |
| HIV Products Other HIV | $500M | ▲ 15.2% |
| HIV Products Symtuza Revenue Share | $495M | ▼ 16.4% |
| Cell Therapy Products Tecartus | $344M | ▼ 14.6% |
| Other Products Other | $290M | ▼ 18.5% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $20.9B | 70.9% | ▲ 1.4% |
| Europe | $5.1B | 17.2% | ▲ 9.3% |
| Rest of World | $3.5B | 11.9% | ▼ 0.7% |
From Gilead Sciences's 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Gilead Sciences | $30.99bn | 6.5% | 4.2% |
| Amgen | $38.09bn | 9.1% | 12.7% |
| Regeneron Pharmaceuticals | $16.90bn | 18.6% | 8.9% |
| AbbVie | $64.39bn | 10.4% | 4.7% |
| Vertex Pharmaceuticals | $12.59bn | 10.2% | 9.8% |
| Biogen | $10.30bn | 2.3% | 1.0% |
Compare with peers
- Amgen revenue
- Regeneron Pharmaceuticals revenue
- AbbVie revenue
- Vertex Pharmaceuticals revenue
- Biogen revenue
Head to head: AMGN vs GILDGILD vs REGNABBV vs GILD
More: Biotechnology stocks compared, Health Care sector, rankings of US companies